346 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
efficacy or safety, trial design, labeling, or manufacturing. A regulatory application for R/R DLBCL and R/R FL remains under review in the EU.
In 2023 … research programs; the likelihood and timing of
achieving any of the anticipated milestones described in this press release; safety issues resulting
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
and timing of achieving any of the anticipated milestones described in this press release; safety issues
resulting from the administration of Regeneron's
8-K
EX-99.1
w9o amm7ze
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
4ujthesruk70pg6f963
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T/A
EX-99
14srh95tcqxs nau
25 Sep 23
Third party tender offer statement (amended)
8:48am
SC TO-T
EX-99
fuftz mzijg
25 Aug 23
Third party tender offer statement
7:46am
SC TO-C
EX-99.2
wmeofsr
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
EX-99.1
4ws iwwcv
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
l6ad4dj0n4mbvz
9 Aug 23
Information about tender offer
4:15pm
8-K
EX-99.1
6evkuxiyfsaow1gy
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-99.1
jn91m0ya1b3a 11wn
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
8-K
EX-10.1
l0a2qqj
29 Mar 23
Entry into a Material Definitive Agreement
4:01pm